Physician profile
John L Palcheff
NPI 1760442032
$12,928.77
in general payments reported to CMS, 2019-2025
52 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,832 · 2020: $1,381 · 2021: $2,576 · 2022: $1,625 · 2023: $1,832 · 2024: $2,039 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,515.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,606.61 | 2019-2025 | |
| Novo Nordisk INC | $1,499.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,378.89 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $1,372.40 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $726.11 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $713.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $706.04 | 2019-2025 | Spravato, Xarelto |
| Pfizer INC. | $573.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $420.13 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $364.91 | 2019-2024 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $267.30 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $256.66 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $240.39 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $236.56 | 2023-2025 | Ingrezza, Ongentys |
| Amarin Pharma, INC. | $235.71 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Palcheff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.